Athira Pharma, Inc.·4

Mar 4, 4:31 PM ET

Renninger Robert 4

4 · Athira Pharma, Inc. · Filed Mar 4, 2025

Insider Transaction Report

Form 4
Period: 2025-03-03
Renninger Robert
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-03-03+58,50058,500 total
    Exercise: $0.38Exp: 2035-03-02Common Stock (58,500 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-03-03+73,35073,350 total
    Exercise: $0.38Exp: 2035-03-02Common Stock (73,350 underlying)
  • Award

    Restricted Stock Units

    2025-03-03+39,00039,000 total
    Common Stock (39,000 underlying)
Footnotes (4)
  • [F1]The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
  • [F2]One fourth (1/4th) of shares subject to the option shall be scheduled to vest on the one (1)-year anniversary of the anniversary of the grant date, and one thirty-sixth (1/36th) of the Shares subject to the Option each month thereafter on the same day of the month as the grant date subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
  • [F3]Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
  • [F4]100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.

Documents

1 file
  • 4
    form4-03042025_090322.xmlPrimary